We have located links that may give you full text access.
A Pilot Study of RSK4 Expression in Patients with Human Non-Small Cell Lung Carcinoma.
BACKGROUND: Lung cancer represents the leading cause of cancer deaths worldwide, with non-small cell lung carcinoma (NSCLC) comprising the most common type of lung cancer.
OBJECTIVE: The aim of this pilot study was to ascertain RSK4 expression at both the gene and protein level in normal and cancerous tissue of patients with NSCLC.
METHODS: From January 2015 to December 2015, a total of forty patients diagnosed with NSCLC who underwent surgery were recruited into this study. All NSCLC diagnoses were confirmed by pathological examination. Normal and cancerous lung tissues were collected via surgical dissection. RSK4 gene and protein expression levels were ascertained using reverse transcription-polymerase chain reaction amplification and immunohistochemistry, respectively. Expression levels and patient pathological clinical parameters were compared by semi-quantitative method.
RESULTS: Both RSK4 gene and protein expression levels were significantly reduced in patient cancerous tissue compared to their normal lung tissue ( P <0.01).
CONCLUSIONS: RSK4 expression is associated with clinical and pathological staging of NSCLC. Our preliminary data from this pilot study suggest that RSK4 constitutes a putative tumor suppressor gene for NSCLC. The relationship between RSK4 gene expression and NSCLC prognosis and clinical outcome needs to be further studied in a multi-center cohort study with a large patient sample.
OBJECTIVE: The aim of this pilot study was to ascertain RSK4 expression at both the gene and protein level in normal and cancerous tissue of patients with NSCLC.
METHODS: From January 2015 to December 2015, a total of forty patients diagnosed with NSCLC who underwent surgery were recruited into this study. All NSCLC diagnoses were confirmed by pathological examination. Normal and cancerous lung tissues were collected via surgical dissection. RSK4 gene and protein expression levels were ascertained using reverse transcription-polymerase chain reaction amplification and immunohistochemistry, respectively. Expression levels and patient pathological clinical parameters were compared by semi-quantitative method.
RESULTS: Both RSK4 gene and protein expression levels were significantly reduced in patient cancerous tissue compared to their normal lung tissue ( P <0.01).
CONCLUSIONS: RSK4 expression is associated with clinical and pathological staging of NSCLC. Our preliminary data from this pilot study suggest that RSK4 constitutes a putative tumor suppressor gene for NSCLC. The relationship between RSK4 gene expression and NSCLC prognosis and clinical outcome needs to be further studied in a multi-center cohort study with a large patient sample.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app